Dr. Sushant Kamath is currently, Senior Manager - Risk Assessment in the Global Preclinical & Product Safety division of Abbott Healthcare Pvt Ltd., where he is involved in toxicological risk assessment of Abbott's product portfolio. He is involved in Toxicological Risk Assessment of chemicals through AI/ML, QSAR and Read-across methods. Further, he is responsible for scientific delivery and strategic development of Nonclinical Safety studies/bridging studies for generics and fixed-dose combinations for registrations in global markets.
Dr. Kamath is an American-board certified Toxicologist. He earned his PhD in Toxicology from SASTRA University working on a project funded by the Department of Science & Technology (DST), Government of India. He has worked on risk assessment of metal-based traditional medicines and carried out preclinical toxicity studies to understand systemic as well genetic toxicity of metal-based traditional drugs.
Prior to joining Abbott, Dr. Kamath worked in different domains like BA/BE studies and in In Vitro DMPK.
Dr. Kamath's long term goal is to work towards establishing New Approach Methods (NAMs) and AI-based models in line with the 3Rs principles for animal free testing of drug products.